中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
5期
629-633
,共5页
环磷酰胺%节拍化疗%重组人血管内皮抑制素%非小细胞肺癌
環燐酰胺%節拍化療%重組人血管內皮抑製素%非小細胞肺癌
배린선알%절박화료%중조인혈관내피억제소%비소세포폐암
Cyclophosphamide%Metronomic chemotherapy%Recombinant human endostatin%Non-small cell lung cancer
目的 探讨环磷酰胺节拍化疗联合重组人血管内皮抑制素用于非小细胞肺腺癌维持治疗的近期和远期疗效.方法 选取2011年1月至2013年1月经病理确诊的86例晚期非小细胞肺腺癌患者,在接受最大耐受剂量环磷酰胺化疗4个周期后,按随机数字表法分为观察组和对照组.观察组予以环磷酰胺节拍化疗联合重组人血管内皮抑制素治疗,对照组仅予以环磷酰胺节拍化疗治疗,对比2组患者维持治疗6周后的外周血T细胞亚群、细胞因子水平,近期和远期临床疗效及不良反应.结果 观察组维持治疗前和维持治疗6周后血清可溶性Fas (sFas)、干扰素γ、肿瘤坏死因子α(TNF-α)、白细胞介素(IL)-2比较分别为(6 102 ±205) ng/L比(4 892±195) ng/L、(7.8±2.8)％比(15.2±2.4)％、(6.6±2.1)％比(7.7±2.2)％、(9.2±1.1)％比(11.3±1.7)％,对照组维持治疗前和维持治疗6周后sFas,干扰素γ,TNF-α,IL-2比较分别为(6 096±199) ng/L比(5 816±201)ng/L、(7.8±3.1)％比(5.5±2.4)％、(6.6±1.5)％比(7.4±0.5)％、(9.2±1.4)％比(10.6±1.8)％,2组患者治疗6周后sFas水平明显低于治疗前,干扰素γ,TNF-α,IL-2水平均明显高于治疗前(P＜0.05);观察组治疗6周后sFas水平均明显低于对照组,干扰素γ、TNF-α、IL-2水平明显高于对照组(P＜0.05).观察组治疗6周后有效率明显高于对照组[35.7％ (15/42)比13.6％ (6/44),P＜0.05];2组无进展生存期和总生存期差异无统计学意义(P＞0.05).2组患者不良反应发生率差异无统计学意义(P=0.465).结论 采用环磷酰胺节拍化疗联合重组人血管内皮抑制素用于非小细胞肺腺癌维持治疗,可明显提高患者免疫力,改善临床疗效.
目的 探討環燐酰胺節拍化療聯閤重組人血管內皮抑製素用于非小細胞肺腺癌維持治療的近期和遠期療效.方法 選取2011年1月至2013年1月經病理確診的86例晚期非小細胞肺腺癌患者,在接受最大耐受劑量環燐酰胺化療4箇週期後,按隨機數字錶法分為觀察組和對照組.觀察組予以環燐酰胺節拍化療聯閤重組人血管內皮抑製素治療,對照組僅予以環燐酰胺節拍化療治療,對比2組患者維持治療6週後的外週血T細胞亞群、細胞因子水平,近期和遠期臨床療效及不良反應.結果 觀察組維持治療前和維持治療6週後血清可溶性Fas (sFas)、榦擾素γ、腫瘤壞死因子α(TNF-α)、白細胞介素(IL)-2比較分彆為(6 102 ±205) ng/L比(4 892±195) ng/L、(7.8±2.8)％比(15.2±2.4)％、(6.6±2.1)％比(7.7±2.2)％、(9.2±1.1)％比(11.3±1.7)％,對照組維持治療前和維持治療6週後sFas,榦擾素γ,TNF-α,IL-2比較分彆為(6 096±199) ng/L比(5 816±201)ng/L、(7.8±3.1)％比(5.5±2.4)％、(6.6±1.5)％比(7.4±0.5)％、(9.2±1.4)％比(10.6±1.8)％,2組患者治療6週後sFas水平明顯低于治療前,榦擾素γ,TNF-α,IL-2水平均明顯高于治療前(P＜0.05);觀察組治療6週後sFas水平均明顯低于對照組,榦擾素γ、TNF-α、IL-2水平明顯高于對照組(P＜0.05).觀察組治療6週後有效率明顯高于對照組[35.7％ (15/42)比13.6％ (6/44),P＜0.05];2組無進展生存期和總生存期差異無統計學意義(P＞0.05).2組患者不良反應髮生率差異無統計學意義(P=0.465).結論 採用環燐酰胺節拍化療聯閤重組人血管內皮抑製素用于非小細胞肺腺癌維持治療,可明顯提高患者免疫力,改善臨床療效.
목적 탐토배린선알절박화료연합중조인혈관내피억제소용우비소세포폐선암유지치료적근기화원기료효.방법 선취2011년1월지2013년1월경병리학진적86례만기비소세포폐선암환자,재접수최대내수제량배린선알화료4개주기후,안수궤수자표법분위관찰조화대조조.관찰조여이배린선알절박화료연합중조인혈관내피억제소치료,대조조부여이배린선알절박화료치료,대비2조환자유지치료6주후적외주혈T세포아군、세포인자수평,근기화원기림상료효급불량반응.결과 관찰조유지치료전화유지치료6주후혈청가용성Fas (sFas)、간우소γ、종류배사인자α(TNF-α)、백세포개소(IL)-2비교분별위(6 102 ±205) ng/L비(4 892±195) ng/L、(7.8±2.8)％비(15.2±2.4)％、(6.6±2.1)％비(7.7±2.2)％、(9.2±1.1)％비(11.3±1.7)％,대조조유지치료전화유지치료6주후sFas,간우소γ,TNF-α,IL-2비교분별위(6 096±199) ng/L비(5 816±201)ng/L、(7.8±3.1)％비(5.5±2.4)％、(6.6±1.5)％비(7.4±0.5)％、(9.2±1.4)％비(10.6±1.8)％,2조환자치료6주후sFas수평명현저우치료전,간우소γ,TNF-α,IL-2수평균명현고우치료전(P＜0.05);관찰조치료6주후sFas수평균명현저우대조조,간우소γ、TNF-α、IL-2수평명현고우대조조(P＜0.05).관찰조치료6주후유효솔명현고우대조조[35.7％ (15/42)비13.6％ (6/44),P＜0.05];2조무진전생존기화총생존기차이무통계학의의(P＞0.05).2조환자불량반응발생솔차이무통계학의의(P=0.465).결론 채용배린선알절박화료연합중조인혈관내피억제소용우비소세포폐선암유지치료,가명현제고환자면역력,개선림상료효.
Objective To analyze the short-term and long-term efficiency of cyclophosphamide (CPA) metronomic chemotherapy (MET) combined with recombinant human endostatin (Endostar) in maintenance treatment of non-small cell lung adenocarcinoma (NSCLC).Methods Totally 86 patients of advanced NSCLC confirmed by pathology from January 2011 to January 2013 were enrolled.After 4 cycles of maximum tolerated dose of CPA,the patients were randomly divided into observation group receiving CPA MET combined with Endostar and control group receiving CPA MET only.After six weeks of maintenance treatment,the peripheral blood T cell subsets,cytokine levels,short-term and long-term clinical efficacy and adverse reaction were compared between the two groups.Results The serum soluble Fas (sFas) was significantly reduced,the Interferon (IFN)-γ,tumor necrosis factor (TNF)-α and interleukin (IL)-2 were significantly increased after 6 weeks of maintenance treatment,compared with those before treatment in both observation group [(4 892 ± 195) ng/L vs (6 102 ±205) ng/L,(15.2 ±2.4)％ vs (7.8 ±2.8)％,(7.7 ±2.2)％ vs (6.6 ±2.1)％,(11.3±1.7)％ vs (9.2±1.1)％] and control group [(5 816±201) ng/L vs (6 096 ± 199) ng/L,(5.5 ±2.4)％ vs (7.8 ±3.1)％,(7.4 ± 0.5)％ vs (6.6±1.5)％,(10.6±1.8)％ vs (9.2±1.4)％] (P＜0.05).After6 weeks of maintenance treatment,sFas was significantly lower,and IFN-γ,TNF-α,IL-2 levels were significantly higher in observation group compare with those in control group (all P ＜ 0.05).After 6 weeks of treatment,the effective rate in observation group was significantly higher than that in control group [35.7％ (15/42) vs 13.6％ (6/44),P ＜0.05].There were no significant differences regarding progression free survival and overall survival between the two groups (P ＞ 0.05).The incidence of adverse reactions in the two groups showed no significant difference (P =0.465).Conclusion CPA MET combined with endostar in maintenance treatment of NSCLC can significantly improve the immunity levels and the clinical efficacy.
